The first batch of anti-COVID-19 drug 2-DG, developed by the Defence Research and Development Organisation (DRDO), will be released today Monday by Defence Minister Rajnath Singh and Health Minister Harsh Vardhan.

The 2-DG (2-deoxy-D-glucose), an anti-COVID-19 therapeutic application of the drug, has been developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of Defence Research and Development Organisation (DRDO), in collaboration with Dr Reddys Laboratories (DRL).&nbsp;

The Drugs Controller General of India (DGCI) has approved the oral drug for emergency use as an adjunct therapy in moderate to severe coronavirus patients, the defence ministry said earlier this month.

The officials said the first batch of the drug will be released by the two ministers at an event at the Defence Research and Development Organisation (DRDO) headquarters.

The ministry, on May 8, said the clinical trials of the drug, 2-deoxy-D-glucose (2-DG), showed that it helps in a faster recovery of hospitalised patients and reduces supplemental oxygen dependence.

The drug's approval has come when India is grappling with a record-breaking wave of the coronavirus pandemic that has stretched the country's healthcare infrastructure to its limit.

"In the ongoing second COVID-19 wave, a large number of patients are facing severe oxygen dependency and need hospitalisation. The drug is expected to save precious lives due to the mechanism of its operation in the infected cells. This also reduces the hospital stay of COVID-19 patients," the ministry had said.

The anti-COVID therapeutic application of the drug has been developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS), a leading laboratory of the DRDO, in collaboration with Dr Reddy's Laboratories (DRL) in Hyderabad.

The drug comes in powder form in a sachet and is taken orally by dissolving it in water, the ministry said.

In efficacy trends, patients treated with 2-DG showed a faster symptomatic cure than the standard of care (SoC) on various endpoints.

(With inputs from agencies)

The first batch of anti-COVID-19 drug 2-DG, developed by the Defence Research and Development Organisation (DRDO), will be released today Monday by Defence Minister Rajnath Singh and Health Minister Harsh Vardhan.

The first batch of anti-COVID-19 drug 2-DG, developed by the Defence Research and Development Organisation (DRDO), will be released today Monday by Defence Minister Rajnath Singh and Health Minister Harsh Vardhan. The 2-DG (2-deoxy-D-glucose), an anti-COVID-19 therapeutic application of the drug, has been developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of Defence Research and Development Organisation (DRDO), in collaboration with Dr Reddys Laboratories (DRL). The Drugs Controller General of India (DGCI) has approved the oral drug for emergency use as an adjunct therapy in moderate to severe coronavirus patients, the defence ministry said earlier this month. The officials said the first batch of the drug will be released by the two ministers at an event at the Defence Research and Development Organisation (DRDO) headquarters. The ministry, on May 8, said the clinical trials of the drug, 2-deoxy-D-glucose (2-DG), showed that it helps in a faster recovery of hospitalised patients and reduces supplemental oxygen dependence. The drug's approval has come when India is grappling with a record-breaking wave of the coronavirus pandemic that has stretched the country's healthcare infrastructure to its limit. "In the ongoing second COVID-19 wave, a large number of patients are facing severe oxygen dependency and need hospitalisation. The drug is expected to save precious lives due to the mechanism of its operation in the infected cells. This also reduces the hospital stay of COVID-19 patients," the ministry had said. The anti-COVID therapeutic application of the drug has been developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS), a leading laboratory of the DRDO, in collaboration with Dr Reddy's Laboratories (DRL) in Hyderabad. The drug comes in powder form in a sachet and is taken orally by dissolving it in water, the ministry said. In efficacy trends, patients treated with 2-DG showed a faster symptomatic cure than the standard of care (SoC) on various endpoints. (With inputs from agencies)

COVID-19: DRDO's anti-coronavirus drug 2-DG to be released today

Two individuals lost their lives and at least 120 prisoners tested positive for COVID-19, as per an official on Thursday.

While speaking to the reporters, DIG (Prisons), Subhakanta Mishra said, "Two individuals lost their lives and at least 120 prisoners tested positive for COVID-19.

Patients shifted to COVID-19 hospitals and 449 convicts released on 90-day parole.

"To curb the spread, Mishra informed, "Patnagarh Sub-Jail and a cell of Berhampur Jail has been converted into a COVID-19 care centre. We are looking into the matter." 
 
The COVID-19 caseload in Odisha mounted to 576, 297 as 10,649 more people tested positive for the virus and 19 new deaths pushed the total death toll to 2,251, informed the state health bulletin yesterday. 
 
Odisha has 100,313 active cases, as per the official data, adding that 473,680 patients have so far recovered from the infection.

Two individuals lost their lives and at least 120 prisoners tested positive for COVID-19, as per an official on Thursday. While speaking to the reporters, DIG (Prisons), Subhakanta Mishra said, "Two individuals lost their lives and at least 120 prisoners tested positive for COVID-19.

Two individuals lost their lives and at least 120 prisoners tested positive for COVID-19, as per an official on Thursday. While speaking to the reporters, DIG (Prisons), Subhakanta Mishra said, "Two individuals lost their lives and at least 120 prisoners tested positive for COVID-19. Patients shifted to COVID-19 hospitals and 449 convicts released on 90-day parole. "To curb the spread, Mishra informed, "Patnagarh Sub-Jail and a cell of Berhampur Jail has been converted into a COVID-19 care centre. We are looking into the matter." The COVID-19 caseload in Odisha mounted to 576, 297 as 10,649 more people tested positive for the virus and 19 new deaths pushed the total death toll to 2,251, informed the state health bulletin yesterday. Odisha has 100,313 active cases, as per the official data, adding that 473,680 patients have so far recovered from the infection.

COVID-19 in India: 120 prisoners test positive in Odisha jails

The overall global COVID-19 caseload has topped 160.8 million, while the deaths have surged to more than 3.34 million, according to Johns Hopkins University.

In its latest update on Friday morning, the University`s Center for Systems Science and Engineering (CSSE) revealed that the current global caseload and death toll stood at 160,825,974 and 3,340,130, respectively.

The US continues to be the worst-hit country with the world`s highest number of cases and deaths at 32,852,543 and 584,478, respectively, according to the CSSE.

In terms of infections, India follows in second place with 23,703,665 cases.

The other worst countries with over 3 million cases are Brazil (15,433,989), France (5,902,343), Turkey (5,083,996), Russia (4,857,303), the UK (4,460,405), Italy (4,139,160), Spain (3,598,452), Germany (3,578,125), Argentina (3,242,103) and Colombia (3,067,879), the CSSE figures showed.

In terms of deaths, Brazil comes second with 430,417 fatalities.

Nations with a death toll of over 100,000 are India (258,317), Mexico (219,089), the UK (127,912), Italy (123,745), Russia (112,795) and France (107,411).

The overall global COVID-19 caseload has topped 160.8 million, while the deaths have surged to more than 3.34 million, according to Johns Hopkins University. In its latest update on Friday morning, the University`s Center for Systems Science and Engineering (CSSE) revealed that the current global caseload and death toll stood at 160,825,974 and 3,340,130, respectively.

The overall global COVID-19 caseload has topped 160.8 million, while the deaths have surged to more than 3.34 million, according to Johns Hopkins University. In its latest update on Friday morning, the University`s Center for Systems Science and Engineering (CSSE) revealed that the current global caseload and death toll stood at 160,825,974 and 3,340,130, respectively. The US continues to be the worst-hit country with the world`s highest number of cases and deaths at 32,852,543 and 584,478, respectively, according to the CSSE. In terms of infections, India follows in second place with 23,703,665 cases. The other worst countries with over 3 million cases are Brazil (15,433,989), France (5,902,343), Turkey (5,083,996), Russia (4,857,303), the UK (4,460,405), Italy (4,139,160), Spain (3,598,452), Germany (3,578,125), Argentina (3,242,103) and Colombia (3,067,879), the CSSE figures showed. In terms of deaths, Brazil comes second with 430,417 fatalities. Nations with a death toll of over 100,000 are India (258,317), Mexico (219,089), the UK (127,912), Italy (123,745), Russia (112,795) and France (107,411).

Global COVID-19 caseload tops 160.8 million

The first dose of the Russian COVID-19 vaccine Sputnik V, which has an efficiency of 91.6 per cent, was administered today in India.

The first consignment of imported doses of the Sputnik V vaccine landed in India on May 1, and received regulatory clearance from the Central Drugs Laboratory, Kasauli, on May 13, 2021. 
 
<a href="https://www.wionews.com/science/risk-for-erectile-dysfunction-six-fold-higher-in-men-with-covid-19-384317">Also read: Risk for erectile dysfunction six-fold higher in men with COVID-19</a>

Further consignments of imported doses are expected over the coming months, Dr Reddy's Laboratories said in a statement. Subsequently, the supply of the Sputnik V vaccine will start from Indian manufacturing partners.&nbsp; 
 
<a href="https://www.wionews.com/photos/countries-ripped-apart-by-the-covid-19-pandemic-289245#united-states-289230">Pictures: Countries ripped apart by the COVID-19 pandemic</a> 
 
The imported doses of the vaccine are presently priced at an MRP of ₹ 948 + 5% GST per dose, with the possibility of a lower price point when local supply begins.

The company is working closely with its six manufacturing partners in India to fulfil regulatory requirements to ensure smooth and timely supply.

Dr Reddy`s will work closely with stakeholders in the Government and private sector in India to ensure the widest possible reach of the Sputnik V vaccine as part of the national inoculation effort. This is a reaffirmation of the Company`s commitment to exploring every avenue in the fight against the Covid-19 pandemic in India.

G.V. Prasad, Co-Chairman and Managing Director, said: "With the rising cases in India, vaccination is the most effective tool in our battle against Covid-19. Contributing to the vaccination drive in India is our biggest priority right now to help Indians be healthy and safe."&nbsp;

(With inputs from agencies)

The first dose of the Russian COVID-19 vaccine Sputnik V, which has an efficiency of 91.6 per cent, was administered today in India. The first consignment of imported doses of the Sputnik V vaccine landed in India on May 1, and received regulatory clearance from the Central Drugs Laboratory, Kasauli, on May 13, 2021.

The first dose of the Russian COVID-19 vaccine Sputnik V, which has an efficiency of 91.6 per cent, was administered today in India. The first consignment of imported doses of the Sputnik V vaccine landed in India on May 1, and received regulatory clearance from the Central Drugs Laboratory, Kasauli, on May 13, 2021. Also read: Risk for erectile dysfunction six-fold higher in men with COVID-19 Further consignments of imported doses are expected over the coming months, Dr Reddy's Laboratories said in a statement. Subsequently, the supply of the Sputnik V vaccine will start from Indian manufacturing partners. Pictures: Countries ripped apart by the COVID-19 pandemic The imported doses of the vaccine are presently priced at an MRP of ₹ 948 + 5% GST per dose, with the possibility of a lower price point when local supply begins. The company is working closely with its six manufacturing partners in India to fulfil regulatory requirements to ensure smooth and timely supply. Dr Reddy`s will work closely with stakeholders in the Government and private sector in India to ensure the widest possible reach of the Sputnik V vaccine as part of the national inoculation effort. This is a reaffirmation of the Company`s commitment to exploring every avenue in the fight against the Covid-19 pandemic in India. G.V. Prasad, Co-Chairman and Managing Director, said: "With the rising cases in India, vaccination is the most effective tool in our battle against Covid-19. Contributing to the vaccination drive in India is our biggest priority right now to help Indians be healthy and safe." (With inputs from agencies)

Sputnik V in India: Vaccine to cost ₹ 995 per shot, made in India may be cheaper

India on Thursday reported 3,62,727 new Covid cases and 4,120 fatalities, the Union Ministry of Health and Family Welfare said. 
 
On Wednesday, India recorded 4,205 fresh Covid deaths, while on Friday last, the country had recorded its highest ever cases of 4,14,188. 
 
In the past 21 days, India`s daily Covid tally has plateaued over the 300,000-mark and over 3,000 casualties for a fortnight. 
 
India`s total tally of COVID-19 cases now stands at 23.7 million with 37 mn active cases and 2,58,317 deaths so far. 
 
According to the Health Ministry, a total of 3,52,181 people have been discharged in the last 24 hours, with 19.7 mn being cured of Covid to date. 
 
The Health Ministry said that a total of 177 mn people have been vaccinated so far in the country, including 18 million who were administered vaccines in the last 24 hours. 
 
According to the Indian Council of Medical Research (ICMR), 309 mn samples have been tested up to May 12 for Covid-19. Of these 18 mn samples were tested on Wednesday.

India on Thursday reported 3,62,727 new Covid cases and 4,120 fatalities, the Union Ministry of Health and Family Welfare said. On Wednesday, India recorded 4,205 fresh Covid deaths, while on Friday last, the country had recorded its highest ever cases of 4,14,188.

India on Thursday reported 3,62,727 new Covid cases and 4,120 fatalities, the Union Ministry of Health and Family Welfare said. On Wednesday, India recorded 4,205 fresh Covid deaths, while on Friday last, the country had recorded its highest ever cases of 4,14,188. In the past 21 days, India`s daily Covid tally has plateaued over the 300,000-mark and over 3,000 casualties for a fortnight. India`s total tally of COVID-19 cases now stands at 23.7 million with 37 mn active cases and 2,58,317 deaths so far. According to the Health Ministry, a total of 3,52,181 people have been discharged in the last 24 hours, with 19.7 mn being cured of Covid to date. The Health Ministry said that a total of 177 mn people have been vaccinated so far in the country, including 18 million who were administered vaccines in the last 24 hours. According to the Indian Council of Medical Research (ICMR), 309 mn samples have been tested up to May 12 for Covid-19. Of these 18 mn samples were tested on Wednesday.

COVID-19: India clocks more than 362,000 fresh Covid cases, 4,120 deaths

An aircraft carrying 176 ventilators from Germany, 324 oxygen cylinders from Finland, and 10 oxygen cylinders from Greece, arrived in Delhi on early Thursday morning.

External Affairs Ministry (EAM) spokesperson Arindam Bagchi termed this COVID assistance from European countries as a "hallmark of India-EU relations.

"Spirit of solidarity, and cooperation - a hallmark of India-EU relations. Aircraft arrives, carrying 176 ventilators from Germany, 324 O2 cylinders from Finland, and 10 O2 cylinders from Greece. Value the continuing support from our EU partners," EAM spokesperson tweeted.

Last week, Germany had sent an oxygen generating plant as part of COVID-19 assistance to India. The member states of the EU are delivering medical aid following India`s request for support as the country has witnessed a record surge in COVID-19 cases in the second wave of the pandemic.

India reported 3,62,727 new COVID-19 cases, and 4,120 deaths in the last 24 hours, as per Union Health Ministry`s data on Thursday.

The aid is being provided through the EU Civil Protection Mechanism, which is coordinated by the Emergency Response Coordination Centre of the European Commission. Several countries like Romania, Italy, Germany, France, and Belgium have already sent in the supplies.

An aircraft carrying 176 ventilators from Germany, 324 oxygen cylinders from Finland, and 10 oxygen cylinders from Greece, arrived in Delhi on early Thursday morning.

An aircraft carrying 176 ventilators from Germany, 324 oxygen cylinders from Finland, and 10 oxygen cylinders from Greece, arrived in Delhi on early Thursday morning. External Affairs Ministry (EAM) spokesperson Arindam Bagchi termed this COVID assistance from European countries as a "hallmark of India-EU relations. "Spirit of solidarity, and cooperation - a hallmark of India-EU relations. Aircraft arrives, carrying 176 ventilators from Germany, 324 O2 cylinders from Finland, and 10 O2 cylinders from Greece. Value the continuing support from our EU partners," EAM spokesperson tweeted. Last week, Germany had sent an oxygen generating plant as part of COVID-19 assistance to India. The member states of the EU are delivering medical aid following India`s request for support as the country has witnessed a record surge in COVID-19 cases in the second wave of the pandemic. India reported 3,62,727 new COVID-19 cases, and 4,120 deaths in the last 24 hours, as per Union Health Ministry`s data on Thursday. The aid is being provided through the EU Civil Protection Mechanism, which is coordinated by the Emergency Response Coordination Centre of the European Commission. Several countries like Romania, Italy, Germany, France, and Belgium have already sent in the supplies.

COVID-19: More ventilators, oxygen cylinders arrive in India from Europe

The National Technical Advisory Group on Immunisation in India (NTAGI) has recommended increasing the gap between two doses of Covishield vaccine to 12-16 weeks.

No change has been suggested for the dosage interval of Covaxin by the National Technical Advisory Group on Immunisation (NTAGI). 
 
The National Technical Advisory Group on Immunisation in India (NTAGI) fulfils a need for informing decision-making concerning the introduction of new vaccines and strengthening the Universal Immunisation Programme (UIP).&nbsp;

According to the current protocol, the vaccine must be taken four to eight weeks after recovery from COVID-19 infection.

This is the second increase in the interval for Covishield in three months.&nbsp;

In March, the Centre told states and UTs to increase the gap from 28 days to six to eight weeks for better results.&nbsp;

These recommendations will be sent to NEGVA - the National Expert Group on Vaccine Administration - for approval before the changes and suggestions are implemented.

Earlier, a study published in the medical journal The Lancet on February 19 claimed a 26.2 per cent increase - from 55.1 per cent to 81.3 per cent - if doses were spaced 12 or more weeks apart.

NTAGI comprises government representatives from the Department of Women and Child Development, internal finance division in Ministry of Health and Family Welfare, Department of Biotechnology, Drug Controller General of India (DCGI) along health experts. India started the world`s largest vaccination drive on January 16 this year in a phased manner with healthcare workers (HCWs) getting inoculated first.&nbsp;

The vaccination of frontline workers (FLWs) started on February 2. The next phase of Covid-19 vaccination commenced from March 1 for those over 60 years of age and for people aged 45 and above with specified co-morbid conditions. India launched vaccination for all people aged more than 45 from April 1.

(With inputs from agencies)

The National Technical Advisory Group on Immunisation in India (NTAGI) has recommended increasing the gap between two doses of Covishield vaccine to 12-16 weeks.

The National Technical Advisory Group on Immunisation in India (NTAGI) has recommended increasing the gap between two doses of Covishield vaccine to 12-16 weeks. No change has been suggested for the dosage interval of Covaxin by the National Technical Advisory Group on Immunisation (NTAGI). The National Technical Advisory Group on Immunisation in India (NTAGI) fulfils a need for informing decision-making concerning the introduction of new vaccines and strengthening the Universal Immunisation Programme (UIP). According to the current protocol, the vaccine must be taken four to eight weeks after recovery from COVID-19 infection. This is the second increase in the interval for Covishield in three months. In March, the Centre told states and UTs to increase the gap from 28 days to six to eight weeks for better results. These recommendations will be sent to NEGVA - the National Expert Group on Vaccine Administration - for approval before the changes and suggestions are implemented. Earlier, a study published in the medical journal The Lancet on February 19 claimed a 26.2 per cent increase - from 55.1 per cent to 81.3 per cent - if doses were spaced 12 or more weeks apart. NTAGI comprises government representatives from the Department of Women and Child Development, internal finance division in Ministry of Health and Family Welfare, Department of Biotechnology, Drug Controller General of India (DCGI) along health experts. India started the world`s largest vaccination drive on January 16 this year in a phased manner with healthcare workers (HCWs) getting inoculated first. The vaccination of frontline workers (FLWs) started on February 2. The next phase of Covid-19 vaccination commenced from March 1 for those over 60 years of age and for people aged 45 and above with specified co-morbid conditions. India launched vaccination for all people aged more than 45 from April 1. (With inputs from agencies)

COVID-19: Indian medical body recommends 12-16 week gap between Covishield doses, no change for Covaxin

The World Health Organization (WHO) has said in its COVID-19 Weekly Epidemiological Update that vaccines by Pfizer and Moderna have shown decreased effectiveness against the double mutant variants discovered in India. 
 
<a href="https://www.wionews.com/india-news/who-hasnt-associated-the-term-indian-variant-with-b1617-covid-19-variant-govt-384480">Also read | WHO hasn't associated the term 'Indian variant' with B.1.617 COVID-19 variant: Govt</a> 
 
“Potential impacts of B.1.617 lineage on the effectiveness of vaccines or therapeutics, or reinfection risks, remain uncertain. Preliminary laboratory studies awaiting peer review suggest a limited reduction in neutralisation by antibodies; however, real-world impacts may be limited,” WHO said in its note. 
 
<a href="https://www.wionews.com/india-news/only-india-has-manufacturing-capacity-to-supply-covid-19-vaccine-to-the-world-australian-envoy-to-india-384654">Also read | Only India has the manufacturing capacity to supply COVID-19 vaccine to the world: Australian Envoy to India</a> 
 
"The resurgence in COVID-19 cases and deaths in India has raised questions on the potential role of B.1.617 and other variants (e.g., B.1.1.7) in circulation."

According to the note, outside of India, the United Kingdom has reported the largest number of cases sequenced as B.1.617 sublineages.

The global health agency cited three studies, all of which are awaiting peer review, that showed that antibodies generated by the vaccines developed by Pfizer and Moderna had a significant reduction in the ability to neutralize the mutant virus and its sublineages.

The World Health Organization has linked the massive surge in coronavirus cases in India to religious and political gatherings.&nbsp;

Globally, the coronavirus has now infected over 160 million people and killed more than 3.3 million since the pandemic broke out in December 2019, according to Johns Hopkins University. Over 90 million patients have recovered from the infection.&nbsp;

(With inputs from agencies)

The World Health Organization (WHO) has said in its COVID-19 Weekly Epidemiological Update that vaccines by Pfizer and Moderna have shown decreased effectiveness against the double mutant variants discovered in India.

The World Health Organization (WHO) has said in its COVID-19 Weekly Epidemiological Update that vaccines by Pfizer and Moderna have shown decreased effectiveness against the double mutant variants discovered in India. Also read | WHO hasn't associated the term 'Indian variant' with B.1.617 COVID-19 variant: Govt “Potential impacts of B.1.617 lineage on the effectiveness of vaccines or therapeutics, or reinfection risks, remain uncertain. Preliminary laboratory studies awaiting peer review suggest a limited reduction in neutralisation by antibodies; however, real-world impacts may be limited,” WHO said in its note. Also read | Only India has the manufacturing capacity to supply COVID-19 vaccine to the world: Australian Envoy to India "The resurgence in COVID-19 cases and deaths in India has raised questions on the potential role of B.1.617 and other variants (e.g., B.1.1.7) in circulation." According to the note, outside of India, the United Kingdom has reported the largest number of cases sequenced as B.1.617 sublineages. The global health agency cited three studies, all of which are awaiting peer review, that showed that antibodies generated by the vaccines developed by Pfizer and Moderna had a significant reduction in the ability to neutralize the mutant virus and its sublineages. The World Health Organization has linked the massive surge in coronavirus cases in India to religious and political gatherings. Globally, the coronavirus has now infected over 160 million people and killed more than 3.3 million since the pandemic broke out in December 2019, according to Johns Hopkins University. Over 90 million patients have recovered from the infection. (With inputs from agencies)

Pfizer and Moderna show less efficacy against double mutant discovered in India

After setting new records with over 400,000 cases per day, the COVID-19 positive cases in India have remained below the four lakh mark this week. At the same time, the death toll continues to be a source of alarm.&nbsp;

The total tally of COVID-19 cases in the country now stands at 2,33,40,938.

The active cases have reduced to 37,04,099 comprising 15.87 per cent of the total infections, while the national COVID-19 recovery rate has improved to 83.04 per cent, the data updated at 8 am showed.

The number of people who have recuperated from the disease surged to 1,93,82,642 while the case fatality rate was recorded at 1.09 per cent, the data stated.

India's COVID-19 tally had crossed the two million&nbsp;mark on August 7, three mn on August 23, four mn on September 5 and five mn&nbsp;on September 16.

It went past six mn on September 28, seven mn on October 11, crossed eight mn on October 29, nine mn on November 20 and surpassed the 10 mn&nbsp;mark on December 19. India crossed the grim milestone of 20 mn on May 4.

According to the ICMR, 30,75,83,991 samples have been tested up to May 11 with 19,83,804 samples being tested on Tuesday.

The 4,205 new fatalities include 793 from Maharashtra, 480 from Karnataka, 347 from Delhi, 301 from Uttar Pradesh, 298 from Tamil Nadu, 214 from Punjab, 199 from Chhattisgarh, 169 from Rajasthan, 144 from Haryana, 132 from West Bengal, 118 each from Gujarat and Uttarakhand, 108 from Andhra Pradesh and 103 from Jharkhand.

A total of 2,54,197 deaths have been reported so far in the country including 77,191 from Maharashtra, 20,010 from Delhi, 19,852 from Karnataka, 16,178 from Tamil Nadu, 16,043 from Uttar Pradesh, 12,593 from West Bengal, 10,941 from Chhattisgarh and 10,918 from Punjab.

The health ministry stressed that more than 70 per cent of the deaths occurred due to comorbidities.

"Our figures are being reconciled with the Indian Council of Medical Research," the ministry said on its website, adding that state-wise distribution of figures is subject to further verification and reconciliation.&nbsp;

(With inputs from agencies)

After setting new records with over 400,000 cases per day, the COVID-19 positive cases in India have remained below the four lakh mark this week. At the same time, the death toll continues to be a source of alarm.

After setting new records with over 400,000 cases per day, the COVID-19 positive cases in India have remained below the four lakh mark this week. At the same time, the death toll continues to be a source of alarm. The total tally of COVID-19 cases in the country now stands at 2,33,40,938. The active cases have reduced to 37,04,099 comprising 15.87 per cent of the total infections, while the national COVID-19 recovery rate has improved to 83.04 per cent, the data updated at 8 am showed. The number of people who have recuperated from the disease surged to 1,93,82,642 while the case fatality rate was recorded at 1.09 per cent, the data stated. India's COVID-19 tally had crossed the two million mark on August 7, three mn on August 23, four mn on September 5 and five mn on September 16. It went past six mn on September 28, seven mn on October 11, crossed eight mn on October 29, nine mn on November 20 and surpassed the 10 mn mark on December 19. India crossed the grim milestone of 20 mn on May 4. According to the ICMR, 30,75,83,991 samples have been tested up to May 11 with 19,83,804 samples being tested on Tuesday. The 4,205 new fatalities include 793 from Maharashtra, 480 from Karnataka, 347 from Delhi, 301 from Uttar Pradesh, 298 from Tamil Nadu, 214 from Punjab, 199 from Chhattisgarh, 169 from Rajasthan, 144 from Haryana, 132 from West Bengal, 118 each from Gujarat and Uttarakhand, 108 from Andhra Pradesh and 103 from Jharkhand. A total of 2,54,197 deaths have been reported so far in the country including 77,191 from Maharashtra, 20,010 from Delhi, 19,852 from Karnataka, 16,178 from Tamil Nadu, 16,043 from Uttar Pradesh, 12,593 from West Bengal, 10,941 from Chhattisgarh and 10,918 from Punjab. The health ministry stressed that more than 70 per cent of the deaths occurred due to comorbidities. "Our figures are being reconciled with the Indian Council of Medical Research," the ministry said on its website, adding that state-wise distribution of figures is subject to further verification and reconciliation. (With inputs from agencies)

COVID-19 in India: 3,48,421 fresh cases, 4205 deaths in last 24 hours

The Indian government has issued a statement after a wrong report circulating in&nbsp;media termed the B.1.617 COVID-19 variant as 'Indian variant'. 
 
The Ministry of Health and Family Welfare in a statement said, "several media reports have covered the news of World Health Organisation (WHO) classifying B.1.617 as a variant of global concern. Some of these reports have termed the B.1.617 variant of the coronavirus as an 'Indian Variant'."

<div class="ui-state-default" contenteditable="false">
<div class="twitter-block" draggable="false">
<blockquote class="twitter-tweet">
<a href="https://twitter.com/hashtag/Unite2FightCorona?src=hash&amp;ref_src=twsrc%5Etfw">#Unite2FightCorona</a> 
 
*ATTENTION* 
 
➡️<a href="https://twitter.com/WHO?ref_src=twsrc%5Etfw">@WHO</a> has not associated the term “Indian Variant” with B.1.617, now classified as Variant of Concern.<a href="https://t.co/w8plx3nIY1">https://t.co/w8plx3nIY1</a> <a href="https://t.co/AJSUaUSxDb">pic.twitter.com/AJSUaUSxDb</a>
— Ministry of Health (@MoHFW_INDIA) <a href="https://twitter.com/MoHFW_INDIA/status/1392389523430985730?ref_src=twsrc%5Etfw">May 12, 2021</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<a class="close-mark close-div" href="#" id="jqclosemark">×</a></div>

"These media reports are without any basis, and unfounded." 
 
"This is to clarify that WHO hasn't associated the term 'Indian variant' with the B.1.617 variant...in its 32-page document. The word 'Indian'&nbsp;has not been used in its report on the matter," the statement read. 
 
The regional office for South-East Asia of the WHO has also said that "World Health Organization does not identify viruses or variants with names of countries they are first reported from. We refer to them by their scientific names and request all to do the same for consistency." 
 
The Indian government has been forced to issue this clarification after many media houses started running news reports saying that the WHO&nbsp;has classified an 'Indian Covid variant'&nbsp;as a 'global variant of concern'. 
 
(With inputs from agencies)

The Indian government has issued a statement after a wrong report circulating in media termed the B.1.617 COVID-19 variant as 'Indian variant'. The Ministry of Health and Family Welfare in a statement said, "several media reports have covered the news of World Health Organisation (WHO) classifying B.

The Indian government has issued a statement after a wrong report circulating in media termed the B.1.617 COVID-19 variant as 'Indian variant'. The Ministry of Health and Family Welfare in a statement said, "several media reports have covered the news of World Health Organisation (WHO) classifying B.1.617 as a variant of global concern. Some of these reports have termed the B.1.617 variant of the coronavirus as an 'Indian Variant'." #Unite2FightCorona *ATTENTION* ➡️@WHO has not associated the term “Indian Variant” with B.1.617, now classified as Variant of Concern.https://t.co/w8plx3nIY1 pic.twitter.com/AJSUaUSxDb — Ministry of Health (@MoHFW_INDIA) May 12, 2021 × "These media reports are without any basis, and unfounded." "This is to clarify that WHO hasn't associated the term 'Indian variant' with the B.1.617 variant...in its 32-page document. The word 'Indian' has not been used in its report on the matter," the statement read. The regional office for South-East Asia of the WHO has also said that "World Health Organization does not identify viruses or variants with names of countries they are first reported from. We refer to them by their scientific names and request all to do the same for consistency." The Indian government has been forced to issue this clarification after many media houses started running news reports saying that the WHO has classified an 'Indian Covid variant' as a 'global variant of concern'. (With inputs from agencies)

WHO hasn't associated the term 'Indian variant' with B.1.617 COVID-19 variant: Govt

The head of the main Indian health agency responding to the coronavirus has said districts reporting a high number of infections should remain locked down for another six to eight weeks to control the spread of the rampaging disease. 
 
Dr. Balram Bhargava, head of the Indian Council of Medical Research (ICMR), said in an interview that lockdown restrictions should remain in place in all districts where the rate of infection is above 10% of those tested. 
 
Currently, three-fourths of India`s 718 districts have what is known as a test-positivity rate above 10%, including major cities like New Delhi, Mumbai and the tech hub of Bengaluru. 
 
Bhargava`s comments are the first time a senior government official has outlined how long lockdowns, which already encompass large parts of country, need to continue to rein in the crisis in India. 
 
Prime Minister Narendra Modi`s government has shied away from imposing a nationwide lockdown because of the economic impact and has left it to state governments. 
 
Several states have introduced varying levels of curbs on economic activity and public movement to stop the spread of the virus, which are mostly being reviewed and extended on a weekly or fortnightly basis. 
 
"The high positivity districts should remain (shut). If they come to 5% from 10% (positivity rate) we can open them, but that has to happen. That won`t happen in six-eight weeks, clearly," Bhargava said in an interview at the New Delhi headquarters of the ICMR, the country`s top medical research body. 
 
Referring to the capital, one of India`s hardest hit cities where the positivity rate reached around 35% but has now fallen to about 17%, Bhargava said: "If Delhi is opened tomorrow, it will be a disaster." 
 
India is in deep crisis in the current wave of COVID-19 infections with around 350,000 cases and 4,000 deaths being reported daily. Hospitals and morgues are overflowing, medical staff is exhausted and oxygen and drugs are running short. 
 
Many experts say the actual case tallies and deaths could be five to 10 times higher. 
 
Modi and other top political leaders have faced a public backlash for addressing mass election rallies where no major COVID-19 safety protocols were followed. The federal government also didn`t intervene to stop a religious festival in a northern state in March that was attended by millions of devout Hindus. 
 
`SLIGHT DELAY` 
 
Bhargava did not criticise the Modi government but conceded there had been a delay in responding to the crisis. 
 
"I think the only discontent we have was there was a slight delay accepting the 10% (recommendation), but that did happen," he said. 
 
He said an April 15 meeting of the National Task Force on COVID-19 had made the recommendation to the government to lock down areas with a 10% positivity rate or higher. 
 
Yet, in a televised speech on April 20, Modi dissuaded states and said a lockdown should be used as "last resort" and the focus should remain on "micro containment zones". 
 
On April 26 - more than 10 days after the task force meeting - India`s home (interior) ministry wrote to states, asking them to implement strict measures for "large containment areas" in hard-hit districts, but only for 14 days. 
 
India`s home and health ministries, as well as Modi`s office, did not respond to requests for comment. 
 
Reuters reported earlier this month the head of the National Centre for Disease Control had privately told an online gathering that strict lockdown measures were required in early April. 
 
Two senior ICMR officials told Reuters the organization was frustrated about political leaders addressing large rallies and allowing religious gatherings, saying the actions publicly flouted required safety measures. Modi himself addressed several of the political meetings, maskless. 
 
"Our messaging has been completely incorrect, not in sync with the situation," said one of the officials, referring to the government. "We have miserably failed." 
 
Bhargava denied there was any discontent within the ICMR and added the agency was on the same page with policymakers. Without commenting directly on political leaders, he said mass gatherings during COVID-19 should not be acceptable in India or anywhere else. 
 
"It`s common sense," he said.

The head of the main Indian health agency responding to the coronavirus has said districts reporting a high number of infections should remain locked down for another six to eight weeks to control the spread of the rampaging disease.

The head of the main Indian health agency responding to the coronavirus has said districts reporting a high number of infections should remain locked down for another six to eight weeks to control the spread of the rampaging disease. Dr. Balram Bhargava, head of the Indian Council of Medical Research (ICMR), said in an interview that lockdown restrictions should remain in place in all districts where the rate of infection is above 10% of those tested. Currently, three-fourths of India`s 718 districts have what is known as a test-positivity rate above 10%, including major cities like New Delhi, Mumbai and the tech hub of Bengaluru. Bhargava`s comments are the first time a senior government official has outlined how long lockdowns, which already encompass large parts of country, need to continue to rein in the crisis in India. Prime Minister Narendra Modi`s government has shied away from imposing a nationwide lockdown because of the economic impact and has left it to state governments. Several states have introduced varying levels of curbs on economic activity and public movement to stop the spread of the virus, which are mostly being reviewed and extended on a weekly or fortnightly basis. "The high positivity districts should remain (shut). If they come to 5% from 10% (positivity rate) we can open them, but that has to happen. That won`t happen in six-eight weeks, clearly," Bhargava said in an interview at the New Delhi headquarters of the ICMR, the country`s top medical research body. Referring to the capital, one of India`s hardest hit cities where the positivity rate reached around 35% but has now fallen to about 17%, Bhargava said: "If Delhi is opened tomorrow, it will be a disaster." India is in deep crisis in the current wave of COVID-19 infections with around 350,000 cases and 4,000 deaths being reported daily. Hospitals and morgues are overflowing, medical staff is exhausted and oxygen and drugs are running short. Many experts say the actual case tallies and deaths could be five to 10 times higher. Modi and other top political leaders have faced a public backlash for addressing mass election rallies where no major COVID-19 safety protocols were followed. The federal government also didn`t intervene to stop a religious festival in a northern state in March that was attended by millions of devout Hindus. `SLIGHT DELAY` Bhargava did not criticise the Modi government but conceded there had been a delay in responding to the crisis. "I think the only discontent we have was there was a slight delay accepting the 10% (recommendation), but that did happen," he said. He said an April 15 meeting of the National Task Force on COVID-19 had made the recommendation to the government to lock down areas with a 10% positivity rate or higher. Yet, in a televised speech on April 20, Modi dissuaded states and said a lockdown should be used as "last resort" and the focus should remain on "micro containment zones". On April 26 - more than 10 days after the task force meeting - India`s home (interior) ministry wrote to states, asking them to implement strict measures for "large containment areas" in hard-hit districts, but only for 14 days. India`s home and health ministries, as well as Modi`s office, did not respond to requests for comment. Reuters reported earlier this month the head of the National Centre for Disease Control had privately told an online gathering that strict lockdown measures were required in early April. Two senior ICMR officials told Reuters the organization was frustrated about political leaders addressing large rallies and allowing religious gatherings, saying the actions publicly flouted required safety measures. Modi himself addressed several of the political meetings, maskless. "Our messaging has been completely incorrect, not in sync with the situation," said one of the officials, referring to the government. "We have miserably failed." Bhargava denied there was any discontent within the ICMR and added the agency was on the same page with policymakers. Without commenting directly on political leaders, he said mass gatherings during COVID-19 should not be acceptable in India or anywhere else. "It`s common sense," he said.

Indian health agency chief says most of country should remain locked down for 6-8 weeks

An Indian Air Force plane carrying 200 oxygen concentrators, arrived from the United Kingdom in Chhattisgarh's Raipur on Tuesday night as part of COVID-19 assistance to India.

"IAF C-130 landed with 200 oxygen concentrators which are gifts from the Government of the United Kingdom," said Raipur Airport director Rakesh Ranjan Sahay.

Similarly, medical aid from Netherlands and Switzerland arrived at Delhi airport today.

A flight carrying medical equipment including 200 oxygen concentrators from South Korea has also arrived at Delhi airport today. The spokesperson of the Ministry of External Affairs (MEA) Arindam Bagchi said that cooperation with the Republic of Korea has continued and appreciated the support from the country.

The worsening COVID-19 situation in India has seen a surge in the demand for medical oxygen and beds for the COVID-19 patients. Several countries around the world have come forward to help India as it continues to struggle with the increase in its health infrastructure needs caused by the rising coronavirus cases.

The member states of the European Union are delivering medical aid following India's request for support as the country has witnessed a record surge in COVID-19 cases in the second wave of the pandemic.

The aid is being provided through the EU Civil Protection Mechanism, which is coordinated by the Emergency Response Coordination Centre of the European Commission.

Several countries like Romania, Italy, Germany, France and Belgium have already sent in the supplies.&nbsp;

An Indian Air Force plane carrying 200 oxygen concentrators, arrived from the United Kingdom in Chhattisgarh's Raipur on Tuesday night as part of COVID-19 assistance to India.

An Indian Air Force plane carrying 200 oxygen concentrators, arrived from the United Kingdom in Chhattisgarh's Raipur on Tuesday night as part of COVID-19 assistance to India. "IAF C-130 landed with 200 oxygen concentrators which are gifts from the Government of the United Kingdom," said Raipur Airport director Rakesh Ranjan Sahay. Similarly, medical aid from Netherlands and Switzerland arrived at Delhi airport today. A flight carrying medical equipment including 200 oxygen concentrators from South Korea has also arrived at Delhi airport today. The spokesperson of the Ministry of External Affairs (MEA) Arindam Bagchi said that cooperation with the Republic of Korea has continued and appreciated the support from the country. The worsening COVID-19 situation in India has seen a surge in the demand for medical oxygen and beds for the COVID-19 patients. Several countries around the world have come forward to help India as it continues to struggle with the increase in its health infrastructure needs caused by the rising coronavirus cases. The member states of the European Union are delivering medical aid following India's request for support as the country has witnessed a record surge in COVID-19 cases in the second wave of the pandemic. The aid is being provided through the EU Civil Protection Mechanism, which is coordinated by the Emergency Response Coordination Centre of the European Commission. Several countries like Romania, Italy, Germany, France and Belgium have already sent in the supplies.

COVID-19: India received 200 oxygen concentrators as foreign aid from UK

Mucormycosis, commonly called black fungus, is a serious and rare fungal infection affecting those suffering from coronavirus in India.

The black fungus that invades the brain is being increasingly seen in vulnerable patients in India as the health system continues to struggle amid the pandemic.

This infection caused by a group of fungi called mucormycetes. These are ubiquitous in the environment and can often be seen on rotting food. Despite being common in the environment, it doesn’t cause infection in humans as our immune cells can easily fight such pathogens.&nbsp; 
 
Gravitas: What is Black Fungus or Mucormycosis?

<div class="videoWrapper trancodeVideo"><iframe allowfullscreen="" autoplay="1" class="includeVideo" frameborder="0" height="350" src="https://www.wionews.com/videos/gravitas-what-is-black-fungus-or-mucormycosis-384376/embed" style="width:100%;max-width:560px;" width="560"></iframe></div>

Mucormycosis is a deadly fungal infection found in some Covid-19 patients with uncontrolled diabetes and prolonged intensive care unit (ICU) stay.&nbsp;

How does the infection start and progress?

The Central government in an advisory said the fungal infection mainly affects people who are on medication that reduces their ability to fight environmental pathogens.

The evidence-based advisory for screening, diagnosis and management of the disease was released by the Indian Council of Medical Research (ICMR) and the Union health ministry.

“Mucormycosis, if uncared for, may turn fatal. Sinuses or lungs of such individuals get affected after fungal spores are inhaled from the air,” it said.

How is it diagnosed?

Warning symptoms include pain and redness around the eyes and nose, fever, headache, coughing, shortness of breath, bloody vomits and altered mental status, the advisory stated.&nbsp;

In COVID-19 patients with diabetes and immuno-suppressed individuals, one must suspect mucormycosis if there is sinusitis, one-side facial pain or numbness, blackish discolouration over the bridge of the nose or palate, toothache, blurred or double vision with pain, skin lesion, thrombosis, chest pain and worsening respiratory symptoms, it said.

Major risk factors for this disease include uncontrolled diabetes mellitus, immunosuppression by steroids, prolonged ICU stay, malignancy and voriconazole therapy, the ICMR-health ministry advisory stated. &nbsp;

How is it prevented and treated?

To prevent the disease, blood glucose level should be monitored post-COVID discharge and also in diabetic patients; steroids should be used judiciously incorrect timing, dose and duration; clean sterile water should be used in humidifiers during oxygen therapy, and antibiotics and antifungal medicines should be used correctly, it said.&nbsp;

The disease can be managed by controlling diabetes, discontinuing immunomodulating drugs, reducing steroids and extensive surgical debridement- to remove all necrotic materials, according to the advisory.&nbsp;

Medical treatment includes installing peripherally inserted central catheter, maintaining adequate systemic hydration, infusion of normal saline intravenously before Amphotericin B infusion and anti-fungal therapy for at least six weeks besides monitoring the patient clinically with radio imaging for response and to detect disease progression, it said.&nbsp;

(With inputs from agencies)

Mucormycosis, commonly called black fungus, is a serious and rare fungal infection affecting those suffering from coronavirus in India. The black fungus that invades the brain is being increasingly seen in vulnerable patients in India as the health system continues to struggle amid the pandemic.

Mucormycosis, commonly called black fungus, is a serious and rare fungal infection affecting those suffering from coronavirus in India. The black fungus that invades the brain is being increasingly seen in vulnerable patients in India as the health system continues to struggle amid the pandemic. This infection caused by a group of fungi called mucormycetes. These are ubiquitous in the environment and can often be seen on rotting food. Despite being common in the environment, it doesn’t cause infection in humans as our immune cells can easily fight such pathogens. Gravitas: What is Black Fungus or Mucormycosis? Mucormycosis is a deadly fungal infection found in some Covid-19 patients with uncontrolled diabetes and prolonged intensive care unit (ICU) stay. How does the infection start and progress? The Central government in an advisory said the fungal infection mainly affects people who are on medication that reduces their ability to fight environmental pathogens. The evidence-based advisory for screening, diagnosis and management of the disease was released by the Indian Council of Medical Research (ICMR) and the Union health ministry. “Mucormycosis, if uncared for, may turn fatal. Sinuses or lungs of such individuals get affected after fungal spores are inhaled from the air,” it said. How is it diagnosed? Warning symptoms include pain and redness around the eyes and nose, fever, headache, coughing, shortness of breath, bloody vomits and altered mental status, the advisory stated. In COVID-19 patients with diabetes and immuno-suppressed individuals, one must suspect mucormycosis if there is sinusitis, one-side facial pain or numbness, blackish discolouration over the bridge of the nose or palate, toothache, blurred or double vision with pain, skin lesion, thrombosis, chest pain and worsening respiratory symptoms, it said. Major risk factors for this disease include uncontrolled diabetes mellitus, immunosuppression by steroids, prolonged ICU stay, malignancy and voriconazole therapy, the ICMR-health ministry advisory stated. How is it prevented and treated? To prevent the disease, blood glucose level should be monitored post-COVID discharge and also in diabetic patients; steroids should be used judiciously incorrect timing, dose and duration; clean sterile water should be used in humidifiers during oxygen therapy, and antibiotics and antifungal medicines should be used correctly, it said. The disease can be managed by controlling diabetes, discontinuing immunomodulating drugs, reducing steroids and extensive surgical debridement- to remove all necrotic materials, according to the advisory. Medical treatment includes installing peripherally inserted central catheter, maintaining adequate systemic hydration, infusion of normal saline intravenously before Amphotericin B infusion and anti-fungal therapy for at least six weeks besides monitoring the patient clinically with radio imaging for response and to detect disease progression, it said. (With inputs from agencies)

What is 'Black Fungus' or 'Mucormycosis'?: Symptoms and treatment

Amid the current coronavirus crisis across the country, the University Grants Commission (UGC) has said universities must take care of the on-ground situation before deciding on holding online examinations. 
 
According to the UGC, before conducting online examinations, the Covid-19 guidelines set by the state and Central governments should be strictly adhered to. The safety of students and teachers must be given primary importance during the pandemic. 
 
The statutory body has urged universities across the country to keep their campus premises safe from the pandemic. The UGC has said universities should encourage students and other staff to get vaccinated. 
 
UGC Chairman D.P. Singh has written a letter to universities across the country over tackling Covid-19. The letter said universities should remain united in the fight against the coronavirus pandemic. 
 
In the letter addressed to all vice-chancellors of universities and principals of colleges, the UGC Chairman has said to overcome the Covid-19 crisis, higher education institutions should remain in touch with students, teachers, education staff, officials and their family members. There is a need to work collectively for the physical, mental health and safety of all people, he added. 
 
Meanwhile, the Delhi University Teachers` Association (DUTA) has written a letter to Singh. "We request the UGC to review its decision for the terminal semester year students. We request that the deadline be extended for MPhil, PhD submissions similar to that during the previous year," DUTA said. 
 
According to DUTA, "The families of the teachers who have died in Delhi University (DU) should be granted jobs on compassionate grounds. Also, the overall situation related to the death of teachers in DU has been apprised to the UGC." 
 
DUTA President Rajib Ray has said pension and gratuity should also be given immediately to retired teachers. Additional funds should also be arranged for teachers and staff working on contract during the pandemic, he added.

Amid the current coronavirus crisis across the country, the University Grants Commission (UGC) has said universities must take care of the on-ground situation before deciding on holding online examinations.

Amid the current coronavirus crisis across the country, the University Grants Commission (UGC) has said universities must take care of the on-ground situation before deciding on holding online examinations. According to the UGC, before conducting online examinations, the Covid-19 guidelines set by the state and Central governments should be strictly adhered to. The safety of students and teachers must be given primary importance during the pandemic. The statutory body has urged universities across the country to keep their campus premises safe from the pandemic. The UGC has said universities should encourage students and other staff to get vaccinated. UGC Chairman D.P. Singh has written a letter to universities across the country over tackling Covid-19. The letter said universities should remain united in the fight against the coronavirus pandemic. In the letter addressed to all vice-chancellors of universities and principals of colleges, the UGC Chairman has said to overcome the Covid-19 crisis, higher education institutions should remain in touch with students, teachers, education staff, officials and their family members. There is a need to work collectively for the physical, mental health and safety of all people, he added. Meanwhile, the Delhi University Teachers` Association (DUTA) has written a letter to Singh. "We request the UGC to review its decision for the terminal semester year students. We request that the deadline be extended for MPhil, PhD submissions similar to that during the previous year," DUTA said. According to DUTA, "The families of the teachers who have died in Delhi University (DU) should be granted jobs on compassionate grounds. Also, the overall situation related to the death of teachers in DU has been apprised to the UGC." DUTA President Rajib Ray has said pension and gratuity should also be given immediately to retired teachers. Additional funds should also be arranged for teachers and staff working on contract during the pandemic, he added.

Varsities must ensure safety before holding online exams: UGC

The Union Ministry of Health and Family Welfare on Tuesday informed that cumulatively 9200 oxygen concentrators, 5243 oxygen cylinders and 19 oxygen generation plants have been dispatched across States and UTs for COVID management.

"The Government of India is receiving international donations and aid of COVID-19 relief medical supplies and equipment since April 27, 2021, from different countries/organisations to augment its efforts in fighting the unprecedented surge in COVID in the country", informed an official release.

Various ministries/departments of the Government of India have seamlessly collaborated through a streamlined and systematic mechanism under the "Whole of Government" approach, for expeditiously delivering the incoming global aid to States and UTs.

Worldwide help is being viably apportioned and expeditiously conveyed by the Government of India to Tertiary Care Institutions across States and UTs for COVID management.

"Cumulatively, 9200 Oxygen Concentrators; 5243 Oxygen Cylinders; 19 Oxygen Generation Plants; 5913 ventilators/Bi-PAP; 3.44L Remdesivir vials delivered/ dispatched through road and air, from April 27, 2021, to May 10, 2021", informed the official release.

Major consignments received on May 10, 2021, from UAE, Israel, USA, Netherland include Ventilators/BiPAP/CPAP (610); Oxygen Concentrators (300) and Favipiravir - 12600 strips (each strip contains 40 tablets).

The process of effective immediate allocation and streamlined delivery to the recipient states/UTs and institutions is being comprehensively monitoring on a regular basis by the Union Health Ministry.

A dedicated Coordination Cell has been created in the Union Health Ministry to coordinate the receipt and allocation of foreign COVID relief material as grants, aid and donations. This Cell started functioning on April 26, 2021.

A Standard Operating Procedure has been framed and implemented by the Health Ministry since May 2, 2021.

The Union Ministry of Health and Family Welfare on Tuesday informed that cumulatively 9200 oxygen concentrators, 5243 oxygen cylinders and 19 oxygen generation plants have been dispatched across States and UTs for COVID management.

The Union Ministry of Health and Family Welfare on Tuesday informed that cumulatively 9200 oxygen concentrators, 5243 oxygen cylinders and 19 oxygen generation plants have been dispatched across States and UTs for COVID management. "The Government of India is receiving international donations and aid of COVID-19 relief medical supplies and equipment since April 27, 2021, from different countries/organisations to augment its efforts in fighting the unprecedented surge in COVID in the country", informed an official release. Various ministries/departments of the Government of India have seamlessly collaborated through a streamlined and systematic mechanism under the "Whole of Government" approach, for expeditiously delivering the incoming global aid to States and UTs. Worldwide help is being viably apportioned and expeditiously conveyed by the Government of India to Tertiary Care Institutions across States and UTs for COVID management. "Cumulatively, 9200 Oxygen Concentrators; 5243 Oxygen Cylinders; 19 Oxygen Generation Plants; 5913 ventilators/Bi-PAP; 3.44L Remdesivir vials delivered/ dispatched through road and air, from April 27, 2021, to May 10, 2021", informed the official release. Major consignments received on May 10, 2021, from UAE, Israel, USA, Netherland include Ventilators/BiPAP/CPAP (610); Oxygen Concentrators (300) and Favipiravir - 12600 strips (each strip contains 40 tablets). The process of effective immediate allocation and streamlined delivery to the recipient states/UTs and institutions is being comprehensively monitoring on a regular basis by the Union Health Ministry. A dedicated Coordination Cell has been created in the Union Health Ministry to coordinate the receipt and allocation of foreign COVID relief material as grants, aid and donations. This Cell started functioning on April 26, 2021. A Standard Operating Procedure has been framed and implemented by the Health Ministry since May 2, 2021.

Covid Relief Aid: 9,200 oxygen concentrators,19 oxygen generation plants dispatched to states, UTs

The National Human Rights Commission of India (NHRC) on Tuesday emphasized that the Centre and States need to put their acts together in order to meet the response by setting up universally functional COVID-19 dashboards for real-time information in the public domain on the availability of hospital beds, oxygen, critical care medicines and devices.

It has also asked for setting up 24X7 functional toll-free helplines and fixing the prices of Covid treatment resources.

The Commission, appreciating and taking a note of the ground realities and challenges, as also reported in the media, related to the management of the second wave of Covid -19, has recommended to the Centre and States, through its 2.0 Covid Advisory, that they need to take immediate action against those hoarding and black-marketing essential medicines, oxygen cylinders and critical care devices. It has also asked them to ramp up the production, transportation and distribution of essential resources.

The Commission has sought action taken report within four weeks on the recommendations contained in its Advisory 2.0, already sent to the Secretary, Union Ministry of Health and Family Welfare and the Chief Secretaries of all States and Union Territories by the Secretary-General, NHRC on 4th May 2021.

Some of the other important recommendations in the 2.0 Advisory are:

Any COVID-19 patient who approaches any public health facility should receive the treatment free of cost;

Functional and effective Help-Desks should be set up in all public and private hospitals for a preliminary check-up;

There should be universal coverage and non-discriminatory pricing of COVID vaccines in all health facilities of the country, and if feasible, vaccination should be made free for everyone irrespective of private or public health establishment along with adequate testing facilities for Covid-19 and timely reports;

Management of crematoriums and burial grounds should be improved, using electric crematorium and App-based interventions to be promoted among stakeholders;

The protection of Rights of COVID warriors engaged should be ensured and the body of a deceased Covid patient should be treated with dignity and handed over to the family ensuring all Covid protocols;

Practical time restrictions should be imposed for buying essential commodities during lockdowns.&nbsp;

The National Human Rights Commission of India (NHRC) on Tuesday emphasized that the Centre and States need to put their acts together in order to meet the response by setting up universally functional COVID-19 dashboards for real-time information in the public domain on the availability of hospital beds, oxygen, critical care medicines and devices.

The National Human Rights Commission of India (NHRC) on Tuesday emphasized that the Centre and States need to put their acts together in order to meet the response by setting up universally functional COVID-19 dashboards for real-time information in the public domain on the availability of hospital beds, oxygen, critical care medicines and devices. It has also asked for setting up 24X7 functional toll-free helplines and fixing the prices of Covid treatment resources. The Commission, appreciating and taking a note of the ground realities and challenges, as also reported in the media, related to the management of the second wave of Covid -19, has recommended to the Centre and States, through its 2.0 Covid Advisory, that they need to take immediate action against those hoarding and black-marketing essential medicines, oxygen cylinders and critical care devices. It has also asked them to ramp up the production, transportation and distribution of essential resources. The Commission has sought action taken report within four weeks on the recommendations contained in its Advisory 2.0, already sent to the Secretary, Union Ministry of Health and Family Welfare and the Chief Secretaries of all States and Union Territories by the Secretary-General, NHRC on 4th May 2021. Some of the other important recommendations in the 2.0 Advisory are: Any COVID-19 patient who approaches any public health facility should receive the treatment free of cost; Functional and effective Help-Desks should be set up in all public and private hospitals for a preliminary check-up; There should be universal coverage and non-discriminatory pricing of COVID vaccines in all health facilities of the country, and if feasible, vaccination should be made free for everyone irrespective of private or public health establishment along with adequate testing facilities for Covid-19 and timely reports; Management of crematoriums and burial grounds should be improved, using electric crematorium and App-based interventions to be promoted among stakeholders; The protection of Rights of COVID warriors engaged should be ensured and the body of a deceased Covid patient should be treated with dignity and handed over to the family ensuring all Covid protocols; Practical time restrictions should be imposed for buying essential commodities during lockdowns.

Centre, States should expeditious implement second wave of  Covid-19 Advisory: NHRC

The Health Ministry has urged states to ensure all beneficiaries who have taken the first dose of COVID-19 are prioritised for the second dose.

Union Health Secretary Rajesh Bhushan and Dr R S Sharma, Member, National Expert Group on Vaccine Administration of COVID-19 reviewed the status of vaccination with health secretaries and National Health Mission MDs of states and UTs through a video conference today.

"States to ensure all beneficiaries who have taken the first dose are prioritised for the second doses," Bhushan said.

He stressed the urgent need to address a large number of beneficiaries waiting for the second dose.

A Health Ministry release said states can reserve at least 70 per cent of the vaccines supplied to them from the Government of India channel (free of cost) for second dose vaccination and the remaining 30 per cent for the first dose.

"This however is indicative. States have the liberty to enhance this to as much as 100 per cent. State-wise numbers on CoWIN have been shared with states for their planning purposes," the release said.

It said that the states were asked to undertake an awareness campaign for reinforcing the importance of complete vaccination with two doses of the vaccine.

Presenting details of states who have ensured high coverage of priority groups (like aged 45+, frontline workers and healthcare workers) and the others, the Health Secretary urged states to ensure that priority groups are vaccinated.

The release said states have been informed in a transparent manner in advance about the COVID vaccines being provided to them from Government of India channel.

"The visibility for the forthcoming fortnight is conveyed to them in advance to enable better and more effective planning by them. The next allocation for May 15-31 will be conveyed to them on May 14. It was pointed out that states can utilize the information regarding dose allocation for next 15 days to plan their vaccination sessions," the release said.

States were also urged to minimise vaccine wastage.

"While the overall levels have considerably reduced, Union Health Secretary pointed that there were many states which still needed to substantially reduce the wastage," the release said.

It was suggested to states to retrain and reorient vaccinators to ensure judicious usage of the vaccines.

"All wastage more than the national average hereafter is to be adjusted from the subsequent allocations to that state/UT," the release said.

It was also pointed out that certain states are able to report a negative wastage because the well-trained health workers can extract maximum doses per vial than what is otherwise generally earmarked.

States were also briefed about procurement from the 'Other than Government of India' (OGoI) channel which has been opened in the Liberalised Phase-III Strategy of Vaccination.

In view of the payments pending from states to the private vaccine manufacturers, the states were advised to constitute a dedicated team of two or three senior officers to coordinate with vaccine manufacturers daily and secure supplies promptly. "This team is to also coordinate with private hospitals to facilitate their procurement thereby maintaining the momentum of the overall vaccination exercise in the state," the release said.

The release said CoWIN platform is also being modified to better reflect the changing needs of the vaccination exercise.

Sharma, who is also Chairman of Empowered Group on Technology and Data Management to combat COVID-19, said that CoWIN will shortly provide the flexibility and feature for reserving slots for second dose.

CoWIN will be customised to the extent possible and will also open APIs. The need for IEC campaign for informing people that they should use only one mobile number for both doses for its reflection in their certificate was stressed, the release said.

Sharma reiterated the critical importance of verity and authenticity of data. He also urged states to avoid use of restrictive criteria to uphold the mantra of CoWIN providing vaccination to anyone, anywhere and at anytime.

The Health Ministry has urged states to ensure all beneficiaries who have taken the first dose of COVID-19 are prioritised for the second dose. Union Health Secretary Rajesh Bhushan and Dr R S Sharma, Member, National Expert Group on Vaccine Administration of COVID-19 reviewed the status of vaccination with health secretaries and National Health Mission MDs of states and UTs through a video conference today.

The Health Ministry has urged states to ensure all beneficiaries who have taken the first dose of COVID-19 are prioritised for the second dose. Union Health Secretary Rajesh Bhushan and Dr R S Sharma, Member, National Expert Group on Vaccine Administration of COVID-19 reviewed the status of vaccination with health secretaries and National Health Mission MDs of states and UTs through a video conference today. "States to ensure all beneficiaries who have taken the first dose are prioritised for the second doses," Bhushan said. He stressed the urgent need to address a large number of beneficiaries waiting for the second dose. A Health Ministry release said states can reserve at least 70 per cent of the vaccines supplied to them from the Government of India channel (free of cost) for second dose vaccination and the remaining 30 per cent for the first dose. "This however is indicative. States have the liberty to enhance this to as much as 100 per cent. State-wise numbers on CoWIN have been shared with states for their planning purposes," the release said. It said that the states were asked to undertake an awareness campaign for reinforcing the importance of complete vaccination with two doses of the vaccine. Presenting details of states who have ensured high coverage of priority groups (like aged 45+, frontline workers and healthcare workers) and the others, the Health Secretary urged states to ensure that priority groups are vaccinated. The release said states have been informed in a transparent manner in advance about the COVID vaccines being provided to them from Government of India channel. "The visibility for the forthcoming fortnight is conveyed to them in advance to enable better and more effective planning by them. The next allocation for May 15-31 will be conveyed to them on May 14. It was pointed out that states can utilize the information regarding dose allocation for next 15 days to plan their vaccination sessions," the release said. States were also urged to minimise vaccine wastage. "While the overall levels have considerably reduced, Union Health Secretary pointed that there were many states which still needed to substantially reduce the wastage," the release said. It was suggested to states to retrain and reorient vaccinators to ensure judicious usage of the vaccines. "All wastage more than the national average hereafter is to be adjusted from the subsequent allocations to that state/UT," the release said. It was also pointed out that certain states are able to report a negative wastage because the well-trained health workers can extract maximum doses per vial than what is otherwise generally earmarked. States were also briefed about procurement from the 'Other than Government of India' (OGoI) channel which has been opened in the Liberalised Phase-III Strategy of Vaccination. In view of the payments pending from states to the private vaccine manufacturers, the states were advised to constitute a dedicated team of two or three senior officers to coordinate with vaccine manufacturers daily and secure supplies promptly. "This team is to also coordinate with private hospitals to facilitate their procurement thereby maintaining the momentum of the overall vaccination exercise in the state," the release said. The release said CoWIN platform is also being modified to better reflect the changing needs of the vaccination exercise. Sharma, who is also Chairman of Empowered Group on Technology and Data Management to combat COVID-19, said that CoWIN will shortly provide the flexibility and feature for reserving slots for second dose. CoWIN will be customised to the extent possible and will also open APIs. The need for IEC campaign for informing people that they should use only one mobile number for both doses for its reflection in their certificate was stressed, the release said. Sharma reiterated the critical importance of verity and authenticity of data. He also urged states to avoid use of restrictive criteria to uphold the mantra of CoWIN providing vaccination to anyone, anywhere and at anytime.

Health Ministry calls upon states to prioritize second dose of COVID-19

A man in the United States was arrested on Friday after federal authorities say he fraudulently obtained millions of dollars in coronavirus relief to buy luxurious cars, take lavish vacations and cover personal expenses.

Mustafa Qadiri, 38, obtained about $5 million in Paycheck Protection Program money after claiming to own four businesses, none of which are in business, according to a federal indictment.

The Southern California man has pleaded not guilty to charges he obtained USD 5 million in federal coronavirus-relief loans for phoney businesses. 
 
On May 7 the Official account of the US Attorney's Office for the Central District of California tweeted that "Federal agents have seized three luxury sports cars allegedly purchased by Mustafa Qadiri, 38, of Irvine, with fraudulently obtained COVID-19 Payment Protection Program (PPP) loans."

<div class="ui-state-default" contenteditable="false">
<div class="twitter-block" draggable="false">
<blockquote class="twitter-tweet">
Federal agents have seized three luxury sports cars allegedly purchased by Mustafa Qadiri, 38, of Irvine, with fraudulently obtained COVID-19 Payment Protection Program (PPP) loans. <a href="https://t.co/MIdkjFeZx2">pic.twitter.com/MIdkjFeZx2</a>
— US Attorney L.A. (@USAO_LosAngeles) <a href="https://twitter.com/USAO_LosAngeles/status/1390731502707744770?ref_src=twsrc%5Etfw">May 7, 2021</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<a class="close-mark close-div" href="#" id="jqclosemark">×</a></div>

Qadiri, of Irvine, pleaded not guilty on Friday to multiple charges including bank fraud, wire fraud, aggravated identity theft, and money laundering, according to the US Attorney’s Office.

Qadiri's lawyer did not immediately respond to a request for comment.

Prosecutors said Qadiri listed one of four mortgage companies in multiple applications for PPP loans, and three banks awarded him a total of more than $5 million. The companies he listed do not exist now, prosecutors said.

He received US$5 million in loans that investigators said he used to pay for trips, sports cars and personal expenses.

(With inputs from agencies)

A man in the United States was arrested on Friday after federal authorities say he fraudulently obtained millions of dollars in coronavirus relief to buy luxurious cars, take lavish vacations and cover personal expenses.

A man in the United States was arrested on Friday after federal authorities say he fraudulently obtained millions of dollars in coronavirus relief to buy luxurious cars, take lavish vacations and cover personal expenses. Mustafa Qadiri, 38, obtained about $5 million in Paycheck Protection Program money after claiming to own four businesses, none of which are in business, according to a federal indictment. The Southern California man has pleaded not guilty to charges he obtained USD 5 million in federal coronavirus-relief loans for phoney businesses. On May 7 the Official account of the US Attorney's Office for the Central District of California tweeted that "Federal agents have seized three luxury sports cars allegedly purchased by Mustafa Qadiri, 38, of Irvine, with fraudulently obtained COVID-19 Payment Protection Program (PPP) loans." Federal agents have seized three luxury sports cars allegedly purchased by Mustafa Qadiri, 38, of Irvine, with fraudulently obtained COVID-19 Payment Protection Program (PPP) loans. pic.twitter.com/MIdkjFeZx2 — US Attorney L.A. (@USAO_LosAngeles) May 7, 2021 × Qadiri, of Irvine, pleaded not guilty on Friday to multiple charges including bank fraud, wire fraud, aggravated identity theft, and money laundering, according to the US Attorney’s Office. Qadiri's lawyer did not immediately respond to a request for comment. Prosecutors said Qadiri listed one of four mortgage companies in multiple applications for PPP loans, and three banks awarded him a total of more than $5 million. The companies he listed do not exist now, prosecutors said. He received US$5 million in loans that investigators said he used to pay for trips, sports cars and personal expenses. (With inputs from agencies)

US man buys Ferrari, Lamborghini using $5 million COVID-19 aid

COVID-19 affects different people in different ways. Experts have been warning of long-term complications that the coronavirus can cause.&nbsp;

According to a study by the University of Rome Tor Vergata, COVID-19 increases the risk of developing erectile dysfunction (ED) by nearly six times. Yet another reason to heed public health advice as the coronavirus continues to spread.&nbsp;

The report states that the preliminary numbers also indicated that having Erectile Dysfunction also increased men’s susceptibility to SARS-CoV-2 infection. Men with ED are more than five times more likely to have COVID-19.

For men with a history of COVID-19, the estimated risk of developing Erectile Dysfunction was 5.66 higher. Those numbers remained even after other factors considered.

So particularly for young and healthy people who abruptly develop erectile dysfunction, and especially after having COVID-19, this can be a sign of something more serious going on.

It is advised for Covid survivors that Andrological assessment and tailored treatments should be considered in the follow-up.

Coronavirus global statistics

Global infections: 158,957,229

Global deaths: 3,303,877

Nations with most cases: US (32,744,100), India (22,992,517), Brazil (15,209,990), France (5,841,593), Turkey (5,044,936).

(With inputs from agencies)

COVID-19 affects different people in different ways. Experts have been warning of long-term complications that the coronavirus can cause. According to a study by the University of Rome Tor Vergata, COVID-19 increases the risk of developing erectile dysfunction (ED) by nearly six times.

COVID-19 affects different people in different ways. Experts have been warning of long-term complications that the coronavirus can cause. According to a study by the University of Rome Tor Vergata, COVID-19 increases the risk of developing erectile dysfunction (ED) by nearly six times. Yet another reason to heed public health advice as the coronavirus continues to spread. The report states that the preliminary numbers also indicated that having Erectile Dysfunction also increased men’s susceptibility to SARS-CoV-2 infection. Men with ED are more than five times more likely to have COVID-19. For men with a history of COVID-19, the estimated risk of developing Erectile Dysfunction was 5.66 higher. Those numbers remained even after other factors considered. So particularly for young and healthy people who abruptly develop erectile dysfunction, and especially after having COVID-19, this can be a sign of something more serious going on. It is advised for Covid survivors that Andrological assessment and tailored treatments should be considered in the follow-up. Coronavirus global statistics Global infections: 158,957,229 Global deaths: 3,303,877 Nations with most cases: US (32,744,100), India (22,992,517), Brazil (15,209,990), France (5,841,593), Turkey (5,044,936). (With inputs from agencies)

Risk for erectile dysfunction six-fold higher in men with COVID-19

Individuals who receive a single dose of the AstraZeneca vaccine have approximately 80% lower risk of death with COVID-19 compared with unvaccinated people, according to a new Public Health England (PHE) analysis.

Data from the analyses also showed that protection against death from the Pfizer-BioNTech vaccine rises from approximately 80% after one dose to 97% after two doses. 
 
<a href="https://www.wionews.com/world/us-approves-pfizer-biontechs-covid-vaccine-for-children-aged-12-15-384195">Also read | US approves Pfizer-BioNTech's Covid vaccine for children aged 12-15</a> 
 
At the time when there is a continuous race of efficacy of Covid-19 vaccine candidates across the world, the recent data from the rollout of AstraZeneca's COVID-19 vaccine shows a positive sign.

PHE said the study was the first on protection against mortality from the AstraZeneca vaccine based on data from a real-world setting. The study looked at new symptomatic cases of COVID-19 between December and April and people who died within 28 days of their positive test by vaccination status.

People who had a single dose of the AstraZeneca vaccine were 55% protected against death, with a figure of 44% protection for a single dose of Pfizer, compared to unvaccinated people.&nbsp;

"Combined with the protection vaccines offer against becoming a case in the first place, this is equivalent to approximately 80% protection against mortality in individuals vaccinated with a single dose of either vaccine," PHE said in a statement.

Protection against mortality from the Pfizer-BioNTech vaccine improved to 69% for cases who had their second dose at least a week before they tested positive. Combined with the estimated protection from getting COVID-19 to start with, this is equivalent to an estimated 97% protection, PHE said.

Prime Minister Boris Johnson is set to confirm the further easing of lockdown restrictions in England on Monday, helped in part by the speed of the country's vaccine rollout. In another dataset, PHE said that it was estimated that two doses of the Pfizer-BioNTech vaccine reduce the risk of hospitalisation by 93% for the over 80s.&nbsp;

(With inputs from agencies)

Individuals who receive a single dose of the AstraZeneca vaccine have approximately 80% lower risk of death with COVID-19 compared with unvaccinated people, according to a new Public Health England (PHE) analysis.

Individuals who receive a single dose of the AstraZeneca vaccine have approximately 80% lower risk of death with COVID-19 compared with unvaccinated people, according to a new Public Health England (PHE) analysis. Data from the analyses also showed that protection against death from the Pfizer-BioNTech vaccine rises from approximately 80% after one dose to 97% after two doses. Also read | US approves Pfizer-BioNTech's Covid vaccine for children aged 12-15 At the time when there is a continuous race of efficacy of Covid-19 vaccine candidates across the world, the recent data from the rollout of AstraZeneca's COVID-19 vaccine shows a positive sign. PHE said the study was the first on protection against mortality from the AstraZeneca vaccine based on data from a real-world setting. The study looked at new symptomatic cases of COVID-19 between December and April and people who died within 28 days of their positive test by vaccination status. People who had a single dose of the AstraZeneca vaccine were 55% protected against death, with a figure of 44% protection for a single dose of Pfizer, compared to unvaccinated people. "Combined with the protection vaccines offer against becoming a case in the first place, this is equivalent to approximately 80% protection against mortality in individuals vaccinated with a single dose of either vaccine," PHE said in a statement. Protection against mortality from the Pfizer-BioNTech vaccine improved to 69% for cases who had their second dose at least a week before they tested positive. Combined with the estimated protection from getting COVID-19 to start with, this is equivalent to an estimated 97% protection, PHE said. Prime Minister Boris Johnson is set to confirm the further easing of lockdown restrictions in England on Monday, helped in part by the speed of the country's vaccine rollout. In another dataset, PHE said that it was estimated that two doses of the Pfizer-BioNTech vaccine reduce the risk of hospitalisation by 93% for the over 80s. (With inputs from agencies)

One AstraZeneca Covid vaccine dose cuts death risk by 80%, 2 Pfizer doses by 97%: UK agency

Dr David Nabarro, special envoy on COVID-19 for the World Health Organization (WHO) on Monday said that he would urge people to maintain social distancing and keep using face masks.

Dr Nabarro said: “I’m pleased with the reality that people are being quite cautious, perhaps even a little bit afraid, of what this virus might bring.

“But I think, at the same time, we’ve got to get on with life, and we can’t go on mothballing ourselves forever.

“So, finding a way to restart, despite this fear, is what I think we will have to do," he said.

"We must maintain a very vigilant posture in the coming months because there will, no doubt, be variants appearing but, at the same time, we have to get on with life so in our getting on with life, we have to just be on the lookout for new spikes of disease and deal with them when they come."

"It (the virus) is constantly capable of changing, and as it changes, it has the ability, we believe, and not demonstrated so far, but it could develop the ability to be able to evade the protection that's been given to us by these wonderful vaccines. But we deal with that when it comes. And we deal with it by being on the alert and by being able to pick up new clusters of disease very, very fast and then to deal with them also very fast." he added.

(With inputs from agencies)

Dr David Nabarro, special envoy on COVID-19 for the World Health Organization (WHO) on Monday said that he would urge people to maintain social distancing and keep using face masks.

Dr David Nabarro, special envoy on COVID-19 for the World Health Organization (WHO) on Monday said that he would urge people to maintain social distancing and keep using face masks. Dr Nabarro said: “I’m pleased with the reality that people are being quite cautious, perhaps even a little bit afraid, of what this virus might bring. “But I think, at the same time, we’ve got to get on with life, and we can’t go on mothballing ourselves forever. “So, finding a way to restart, despite this fear, is what I think we will have to do," he said. "We must maintain a very vigilant posture in the coming months because there will, no doubt, be variants appearing but, at the same time, we have to get on with life so in our getting on with life, we have to just be on the lookout for new spikes of disease and deal with them when they come." "It (the virus) is constantly capable of changing, and as it changes, it has the ability, we believe, and not demonstrated so far, but it could develop the ability to be able to evade the protection that's been given to us by these wonderful vaccines. But we deal with that when it comes. And we deal with it by being on the alert and by being able to pick up new clusters of disease very, very fast and then to deal with them also very fast." he added. (With inputs from agencies)

COVID-19: Can't keep on mothballing ourselves, says WHO official

The Himachal Pradesh government has decided to impose ‘corona curfew’ in the state from May 7 till midnight of May 16 to break the chain of Covid-19 transmission.

An FIR will also be registered against families hiding information about COVID-infected patients in Himachal Pradesh's Solang district, according to the office of Gram Panchayat, Solang.&nbsp;

The Gram Panchayat Secretary ordered that shopkeepers found without masks and gloves will be fined Rs 500 because of Corona curfew from midnight of May 6.&nbsp;

It has been mandatory to wear masks at all public places in the village.

People who will be travelling from outside to the village will have to undergo a seven-day quarantine, said the secretary.

Meanwhile, families of COVID patients have to also undergo a 14-day home quarantine.

As per the Union Health Ministry, Himachal Pradesh has 25,902 active COVID cases. In the last 24 hours, the state recorded 2,330 new cases and 32 related deaths.

India recorded a new high of 4,12,262 new Covid cases and 3,980 deaths, taking the country's tally to 2,10,77,410.

(With inputs from agencies)

The Himachal Pradesh government has decided to impose ‘corona curfew’ in the state from May 7 till midnight of May 16 to break the chain of Covid-19 transmission.

The Himachal Pradesh government has decided to impose ‘corona curfew’ in the state from May 7 till midnight of May 16 to break the chain of Covid-19 transmission. An FIR will also be registered against families hiding information about COVID-infected patients in Himachal Pradesh's Solang district, according to the office of Gram Panchayat, Solang. The Gram Panchayat Secretary ordered that shopkeepers found without masks and gloves will be fined Rs 500 because of Corona curfew from midnight of May 6. It has been mandatory to wear masks at all public places in the village. People who will be travelling from outside to the village will have to undergo a seven-day quarantine, said the secretary. Meanwhile, families of COVID patients have to also undergo a 14-day home quarantine. As per the Union Health Ministry, Himachal Pradesh has 25,902 active COVID cases. In the last 24 hours, the state recorded 2,330 new cases and 32 related deaths. India recorded a new high of 4,12,262 new Covid cases and 3,980 deaths, taking the country's tally to 2,10,77,410. (With inputs from agencies)

COVID-19 in Himachal Pradesh: FIR for hiding COVID-infection, fine for not wearing mask

Russia has registered Sputnik Light, the single-dose vaccine against COVID-19, which has an efficacy of 79.4 per cent, the Russian Direct Investment Fund (RDIF) said.

"The Russian Ministry of Health, the Gamaleya National Research Center of Epidemiology and Microbiology and the Russian Direct Investment Fund announce that Sputnik Light, a single dose COVID-19 vaccine, has received authorization for use in Russia. The single-dose Sputnik Light vaccine demonstrated 79.4% efficacy according to analyzed data taken from 28 days after the injection was administered. An efficacy level of near 80% is higher than that of many two-dose vaccines," the RDIF said in a statement.

According to the statement, the efficacy of Sputnik Light was calculated based on data obtained from Russians "vaccinated with a single injection, having not received the second one for any reason during the mass vaccination program between December 5, 2020, and April 15, 2021." 
&nbsp;

<div class="videoWrapper trancodeVideo"><iframe allowfullscreen="" autoplay="1" class="includeVideo" frameborder="0" height="350" src="https://www.wionews.com/videos/covid-19-first-lot-of-russian-vaccine-sputnik-v-arrives-in-india-382006/embed" style="width:100%;max-width:560px;" width="560"></iframe></div>

Sputnik Light is the first component (recombinant human adenovirus serotype number 26 (rAd26)) of the Sputnik V coronavirus vaccine, according to the Russian Direct Investment Fund (RDIF), the sovereign wealth fund marketing the vaccine abroad.

"The Sputnik Light vaccine significantly reduces the possibility of severe cases leading to hospitalization, with only one injection needed. The single-dose regimen solves the challenge of immunizing large groups in a shorter time, which is especially important during the acute phase of the spread of coronavirus, achieving herd immunity faster," said Kirill Dmitriev, CEO of RDIF.

Dmitriev said that the Sputnik Light vaccine will be exported to the international partners "to help increase the rate of vaccinations in several countries in the face of the ongoing fight with the pandemic and new strains of coronavirus".&nbsp;

The Sputnik Light vaccine has received authorization for use in Russia, according to the Russian Ministry of Health, the Gamaleya National Research Center of Epidemiology and Microbiology and the RDIF.On February 21, the Gamaleya Center and RDIF launched a global efficacy study of Sputnik Light.&nbsp;

The Phase III clinical study involving 7,000 people was conducted in multiple countries including Russia, the UAE and Ghana. The RDIF said that the Sputnik Light vaccine is based on a well-studied human adenoviral vector platform that has proven to be safe and effective.&nbsp;

As of May 5, more than 20 million people globally have received the first injection of the Sputnik V vaccine, containing the first component.&nbsp;

"The cost of the Sputnik Light vaccine globally will be less than USD10, while it has simple storage requirements, at +2 +8, which provide for easy logistics. The one-shot regimen allows for the vaccination of large groups of the population in a short time, helping to speed up the fight against the pandemic during the acute phase," the statement read.&nbsp;

Alexander Gintsburg, Director of the Gamaleya National Research Center of Epidemiology and Microbiology, said that Sputnik Light offers strong value in initial vaccination and re-vaccination, as well as boosting efficacy when taken in combination with other vaccines"Sputnik Light will help to prevent the spread of coronavirus through the faster immunization of larger population groups, as well as supporting high immunity levels in those who have already been infected previously," Gintsburg said.

(With inputs from agencies)

Russia has registered Sputnik Light, the single-dose vaccine against COVID-19, which has an efficacy of 79.4 per cent, the Russian Direct Investment Fund (RDIF) said.

Russia has registered Sputnik Light, the single-dose vaccine against COVID-19, which has an efficacy of 79.4 per cent, the Russian Direct Investment Fund (RDIF) said. "The Russian Ministry of Health, the Gamaleya National Research Center of Epidemiology and Microbiology and the Russian Direct Investment Fund announce that Sputnik Light, a single dose COVID-19 vaccine, has received authorization for use in Russia. The single-dose Sputnik Light vaccine demonstrated 79.4% efficacy according to analyzed data taken from 28 days after the injection was administered. An efficacy level of near 80% is higher than that of many two-dose vaccines," the RDIF said in a statement. According to the statement, the efficacy of Sputnik Light was calculated based on data obtained from Russians "vaccinated with a single injection, having not received the second one for any reason during the mass vaccination program between December 5, 2020, and April 15, 2021." Sputnik Light is the first component (recombinant human adenovirus serotype number 26 (rAd26)) of the Sputnik V coronavirus vaccine, according to the Russian Direct Investment Fund (RDIF), the sovereign wealth fund marketing the vaccine abroad. "The Sputnik Light vaccine significantly reduces the possibility of severe cases leading to hospitalization, with only one injection needed. The single-dose regimen solves the challenge of immunizing large groups in a shorter time, which is especially important during the acute phase of the spread of coronavirus, achieving herd immunity faster," said Kirill Dmitriev, CEO of RDIF. Dmitriev said that the Sputnik Light vaccine will be exported to the international partners "to help increase the rate of vaccinations in several countries in the face of the ongoing fight with the pandemic and new strains of coronavirus". The Sputnik Light vaccine has received authorization for use in Russia, according to the Russian Ministry of Health, the Gamaleya National Research Center of Epidemiology and Microbiology and the RDIF.On February 21, the Gamaleya Center and RDIF launched a global efficacy study of Sputnik Light. The Phase III clinical study involving 7,000 people was conducted in multiple countries including Russia, the UAE and Ghana. The RDIF said that the Sputnik Light vaccine is based on a well-studied human adenoviral vector platform that has proven to be safe and effective. As of May 5, more than 20 million people globally have received the first injection of the Sputnik V vaccine, containing the first component. "The cost of the Sputnik Light vaccine globally will be less than USD10, while it has simple storage requirements, at +2 +8, which provide for easy logistics. The one-shot regimen allows for the vaccination of large groups of the population in a short time, helping to speed up the fight against the pandemic during the acute phase," the statement read. Alexander Gintsburg, Director of the Gamaleya National Research Center of Epidemiology and Microbiology, said that Sputnik Light offers strong value in initial vaccination and re-vaccination, as well as boosting efficacy when taken in combination with other vaccines"Sputnik Light will help to prevent the spread of coronavirus through the faster immunization of larger population groups, as well as supporting high immunity levels in those who have already been infected previously," Gintsburg said. (With inputs from agencies)

COVID-19: Russia okays single-dose Sputnik Light vaccine, has 79.4% efficacy

At least 11 patients died at the Government Chengalpattu Medical College Hospital here on Tuesday night. An inquiry has been ordered into the cause of death. 
 
Though it is alleged that the patients died due to oxygen shortage, senior officials said it is not the case as the hospital has sufficient stock. 
 
"As per initial reports, the hospital has sufficient stock of oxygen. It is not an oxygen supply issue. Only an inquiry would reveal as to the cause of death," J. Radhakrishnan, Health Secretary told IANS. 
 
He pointed out there are several other patients who were on oxygen supply and they were not affected. 
 
Couple of days ago at the Government Vellore Medical College Hospital, relatives of patients alleged the deaths of six patients were due to disruption in the supply of oxygen. 
 
According to the official, work on the hospital`s oxygen plant was underway and the relatives of the Covid-19 patients who died alleged that the death was due to disruption in oxygen supply. 
 
"There are over 150 patients in the hospital`s Covid-19 ward. Supply of oxygen to several patients did not get disrupted," the official added. 
 
An inquiry by the Director of Medical Education has been ordered in the case of Government Vellore Medical College Hospital.

At least 11 patients died at the Government Chengalpattu Medical College Hospital here on Tuesday night. An inquiry has been ordered into the cause of death. Though it is alleged that the patients died due to oxygen shortage, senior officials said it is not the case as the hospital has sufficient stock.

At least 11 patients died at the Government Chengalpattu Medical College Hospital here on Tuesday night. An inquiry has been ordered into the cause of death. Though it is alleged that the patients died due to oxygen shortage, senior officials said it is not the case as the hospital has sufficient stock. "As per initial reports, the hospital has sufficient stock of oxygen. It is not an oxygen supply issue. Only an inquiry would reveal as to the cause of death," J. Radhakrishnan, Health Secretary told IANS. He pointed out there are several other patients who were on oxygen supply and they were not affected. Couple of days ago at the Government Vellore Medical College Hospital, relatives of patients alleged the deaths of six patients were due to disruption in the supply of oxygen. According to the official, work on the hospital`s oxygen plant was underway and the relatives of the Covid-19 patients who died alleged that the death was due to disruption in oxygen supply. "There are over 150 patients in the hospital`s Covid-19 ward. Supply of oxygen to several patients did not get disrupted," the official added. An inquiry by the Director of Medical Education has been ordered in the case of Government Vellore Medical College Hospital.

11 patients die at government hospital in Chennai, probe ordered

health-ministry

Health Ministry, News on Health Ministry, stories on Health Ministry, articles on Health Ministry, Health Ministry stories at Wion, Health Ministry news, Health Ministry latest news